Vaccination News Home Page                                            subscribe Vaccination NewsLetter

http://www.neurology.org/cgi/content/abstract/60/8/1241

Neurology 2003;60:1241-1245
© 2003 American Academy of Neurology
 

Views & Reviews
 

Smallpox and smallpox vaccination

Neurological implications

John Booss, MD and Larry E. Davis, MD

From the Department of Veterans Affairs (Dr. Booss), V.A. Connecticut Health Care System, West Haven; Departments of Neurology and Laboratory Medicine (Dr. Booss), Yale University School of Medicine, New Haven, CT; New Mexico VA Health Care System (Dr. Davis); and the Departments of Neurology, Neuroscience, Molecular Genetics, Microbiology, and Immunology (Dr. Davis), University of New Mexico School of Medicine, Albuquerque.

Address correspondence and reprint requests to Dr. John Booss, Neurology Service (200), V.A. Connecticut Health Care System, 950 Campbell Avenue, West Haven, CT 06516; e-mail: john.booss@med.va.gov

Compulsory vaccination was discontinued in the U.S. in 1972; the world was declared free of smallpox infection in 1980. Since that time, no new smallpox infections have been recognized, and only limited numbers of military and laboratory personnel have been vaccinated. As a result, the majority of the U.S. and the world population have no or diminished immunity to smallpox. Widespread vaccination, beginning with the military and health care workers, is now being undertaken. Public health strategies for immunizing the general population include preexposure voluntary vaccination, case surveillance with ring vaccination, and mass vaccination at the time of attack. Cutaneous complications of vaccination occur in immunosuppressed subjects and in those with atopic dermatitis. Among the most serious complications is postvaccinal encephalomyelitis (PVEM). A related condition, postvaccinial encephalopathy (PVE), may be seen in children less than two years of age. There are no markers to predict who will develop PVEM. In the past, mortality was high, ranging from 10 to 50%. The neuropathology of PVEM suggested an immune-mediated attack on the CNS, but the target of the immune response is unknown. Comprehensive programs are needed for surveillance and confirming case definitions for neurologic complications. Multi-institutional controlled trials of antiviral and immune modulating therapy of PVEM should be considered. Neurologists should be actively involved in the planning process for vaccination programs and in the treatment of neurologic complications.

This article has been cited by other articles:

R. T. Johnson Smallpox: The threat of bioterrorism and the risk of the vaccine Neurology, April 22, 2003; 60(8): 1228 - 1229. [Full Text] [PDF]

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.